clouddn.eureka.digital - /NN/NovoSeven Key Components/HQ22NS00006 Components_NovoSeven_PrintCVA/HQ22NS00006_Reference Pack/
[To Parent Directory]
9/2/2022 9:41 AM 6650845 (Copyrights restricted)_Healthcare Improvement Scotland 2012 Sco_v1.0.pdf
9/2/2022 9:42 AM 10716477 (Copyrights restricted)_WHO 2012 WHO recommendations for the pre_v1.0.pdf
9/2/2022 9:39 AM 1502351 1. NovoSeven SmPC, 2018, eMC_v1.0.pdf
9/2/2022 9:30 AM 1417919 11. NovoSeven Approved Package Insert SA_v1.0.pdf
9/2/2022 9:32 AM 713974 2. Rexen P et al. TH Open 2019 3e45_e492019_v2.0.pdf
9/2/2022 9:33 AM 833992 3. Pollard et al., J Haem Pract 2017 4(1) 1_5._v1.0.pdf
9/2/2022 9:29 AM 701543 35_ODEYEMI_2002_v1.0.pdf
9/2/2022 9:29 AM 320280 36_Hart_2002_v1.0.pdf
9/2/2022 9:40 AM 118200 A cost evaluation of treatment alternatives for mild-to-moderate_v1.0.pdf
9/2/2022 9:40 AM 628921 Abshire T, Kenet G 2008 Safety update in the use of recombinanat_v1.0.pdf
9/2/2022 9:31 AM 49746 Abshire T, Kenet G. Haemophilia 14(5)： 898-902, 2008_v1.0.pdf
9/2/2022 9:42 AM 5007065 ACOG Practice Guidelines. Clinical Management Guidelines for Obs_v1.0.pdf
9/2/2022 9:31 AM 1233767 Amano K et al.：Haemophilia 23（1）：50-58, 2016_v1.0.pdf
9/2/2022 9:32 AM 561006 Assessment of in vivo administered recombinant activated factor_v1.0.pdf
9/2/2022 9:30 AM 92735 Balkan C et al.：Haemophilia 16(6)：902-909, 2010_v1.0.pdf
9/2/2022 9:30 AM 152180 Baudo F et al.： Blood 120(1)： 39-46, 2012_v1.0.pdf
9/2/2022 9:32 AM 1310915 Baudo F et al.：Blood 120（1）：39-46, 2012_v1.0.pdf
9/2/2022 9:40 AM 1775267 Bienstock et al. 2021 Postpartum Hemorrhage_v1.0.pdf
9/2/2022 9:30 AM 136578 Boadas A et al.：Haemophilia 17(3)： 422-427, 2011_v1.0.pdf
9/2/2022 9:31 AM 355704 Bolton-Maggs et al, 2006, Br J Haematol_v1.0.pdf
9/2/2022 9:30 AM 1077180 Borg JY et al.：Haemophilia 19（4）：564-570, 2013_v1.0.pdf
9/2/2022 9:32 AM 74843 Borhany, 2012, Haemophilia_v1.0.pdf
9/2/2022 9:33 AM 141031 Bowcutt et al. 2008 Implementation of an intravenous medication_v1.0.pdf
9/2/2022 9:31 AM 765608 Bysted BV et al.： Haemophilia 13(5)： 527-532, 2007_v1.0.pdf
9/2/2022 9:41 AM 1148833 Carroli G et al. 2008 Epidemiology of postpartum haemorrhage a s_v1.0.pdf
9/2/2022 9:32 AM 1454373 Caviglia_2011_v1.0.pdf
9/2/2022 9:42 AM 551603 Christopoulos P et al. 2011 Obstetric hysterectomy A review of c_v1.0.pdf
9/2/2022 9:29 AM 204093 Chung_2004_v1.0.pdf
9/2/2022 9:40 AM 1352541 Collins PW et al.：BMC Res Notes 3 161, 2010_v1.0.pdf
9/2/2022 9:30 AM 1362760 Collins PW, et al., BMC Res Notes, 3：161, 2010_v1.0.pdf
9/2/2022 9:40 AM 252678 Cost and effectiveness of treatments for mild-to-moderate bleedi_v1.0.pdf
9/2/2022 9:39 AM 633645 Cost-effectiveness of recombinant porcine Factor VIII (OBIZUR) f_v2.0.pdf
9/2/2022 9:31 AM 311394 Croom KF, McCormack PL. Biodrugs 22(2)：121-136, 2008_v1.0.pdf
9/2/2022 9:30 AM 460000 de_Souza_2009_v2.0.pdf
9/2/2022 9:32 AM 1130651 Demartis F 2017 Real-World Early Treatment with Room Temperature_v1.0.pdf
9/2/2022 9:28 AM 1115146 Demartis F et al. 2017 Real-World Early Treatment with Room Temp_v1.0.pdf
9/2/2022 9:31 AM 597418 Di Minno et al, 2015, Haematologica_v1.0.pdf
9/2/2022 9:29 AM 532982 DUNDAR_2005_v1.0.pdf
9/2/2022 9:39 AM 39619798 Emicizumab Prophylaxis in Hemophilia A with Inhibitors_v1.0.pdf
9/2/2022 9:43 AM 11763487 EPAR 2022 NovoSeven II-116 CHMP extension of indication variatio_v1.0.pdf
9/2/2022 9:40 AM 98236 Ericsson A, et al. 2012 Swedish Adaptation of Czech Pharmacoeco_v1.0.pdf
9/2/2022 9:29 AM 189555 FDA Approves New Formulation of Coagulation Therapy NovoSeven RT_v1.0.pdf
9/2/2022 9:40 AM 2425882 Feiba PI (Competitor PI)_v2.0.pdf
9/2/2022 9:28 AM 797948 FEIBA Summary of Product Characteristics_v1.0.pdf
9/2/2022 9:40 AM 1095121 Fernandez-Bello 2017 - The pharmacokinetics and pharmacodynamics_v1.0.pdf
9/2/2022 9:31 AM 1090385 Fernández-Bello I, et al. Haemophilia 2017;23(1)868–876._v1.0.pdf
9/2/2022 9:43 AM 176851 GB OBIZUR Summary of Product Characteristics April 2022_v2.0.pdf
9/2/2022 9:32 AM 10278558 GB OBIZUR Summary of Product Characteristics July 2021_v1.0.pdf
9/2/2022 9:32 AM 87804 Giangrande PL et al.： Haemophilia 15（2）：501-508, 2009_v1.0(1).pdf
9/2/2022 9:30 AM 75811 Giangrande PL et al.： Haemophilia 15（2）：501-508, 2009_v1.0.pdf
9/2/2022 9:40 AM 407316 Global causes of maternal death a WHO systematic analysis_v1.0.pdf
9/2/2022 9:30 AM 100820 Goddard 2005 - Case studies orthopaedic surgery in adult patient_v1.0.pdf
9/2/2022 9:30 AM 49664 Goudemand_2004_v2.0.pdf
9/2/2022 9:30 AM 1588269 Green D et al.：Thrombos Haemostas 46（3）：200-203, 1981_v1.0.pdf
9/2/2022 9:40 AM 128310 Guidelines for Emergency Department Management of Individuals wi_v2.0.pdf
9/2/2022 9:43 AM 115356 Hammami MB 2015 Partial Thromboplastin Time, Activated_v1.0.pdf
9/2/2022 9:31 AM 35916 Hammami MB. Partial thromoplastin time, activated. Medscape_v1.0.pdf
9/2/2022 9:31 AM 1406440 Hay CR et al.：Thromb Haemost 7（8）：1463-1467, 1997_v1.0.pdf
9/2/2022 9:29 AM 1274825 Hay CRM, et al British Journal of Haematology 2000; 111 78-90_v1.0.pdf
9/2/2022 9:40 AM 185409 Hedner U 2015 Recombinant activated factor VII 30 years of resea_v1.0.pdf
9/2/2022 9:28 AM 820151 Hedner U. Blood Rev 29(S1： S4-S8, 2015pdf_v1.0.pdf
9/2/2022 9:40 AM 823146 Hedner, 2015, Blood Reviews_v1.0.pdf
9/2/2022 9:28 AM 240634 Hemlibra SmPC January 2021_v3.0.pdf
9/2/2022 9:40 AM 2113131 Hemlibra_SmPC_2018_v1.0.pdf
9/2/2022 9:32 AM 1966815 Hers, Mumford, 2008, Platelets_v1.0.pdf
9/2/2022 9:32 AM 1326074 Hoffman M, Monroe DM. Thromb Haemost 85（6）： 958-965, 2001_v1.0.pdf
9/2/2022 9:28 AM 78521 Hoffman M, Thromb Haemost, 2001, 85, 958-965_Clean_v1.0.pdf
9/2/2022 9:29 AM 263091 Huth-Kuehne_2006_v1.0.pdf
9/2/2022 9:30 AM 1927511 Huth-Kuhne A et al.：Haematologica 94（4）：566-575, 2009_v1.0.pdf
9/2/2022 9:30 AM 1096073 Ingerslev J et al.：Haemostasis 26（S1）： 118-123, 1996_v1.0.pdf
9/2/2022 9:31 AM 605947 Jayakar JP, et al. 2018 Retrospective review of Acquired Haemoph_v1.0.pdf
9/2/2022 9:29 AM 813723 Jimenez_2013_v1.0.pdf
9/2/2022 9:29 AM 1174952 Joshi_2006_v1.0.pdf
9/2/2022 9:28 AM 289201 Jurlander B et al 2001 Recombinant Activated Factor VII (rFVIIa)_v1.0.pdf
9/2/2022 9:32 AM 233373 Kjalke et al, 2001, Br J Haematol_v1.0.pdf
9/2/2022 9:41 AM 10821920 Knight M et al. 2021 Saving Lives, Improving Mothers’ Care - Le_v1.0.pdf
9/2/2022 9:31 AM 1554632 Knoebl P et al.：J Thromb Haemost 10（4）： 622-631, 2012_v1.0.pdf
9/2/2022 9:30 AM 1173477 Kruse-Jarres, et al. 2015. Haemophilia_v1.0.pdf
9/2/2022 9:42 AM 259062 Lavigne-Lissalde 2015 Recombinant human FVIIa for reducing the n_v1.0.pdf
9/2/2022 9:33 AM 212307 Lentz 2014_v1.0.pdf
9/2/2022 9:31 AM 397511 Lentz SR et al 2014 A novel supplemental approach to capturing p_v1.0.pdf
9/2/2022 9:32 AM 222514 Lentz SR et al.： J Thromb Haemost 12（8）：1244-1253, 2014_v1.0.pdf
9/2/2022 9:32 AM 1627924 Lisman et al, 2004, Blood_v1.0.pdf
9/2/2022 9:30 AM 942580 Ma AD et al.：Blood Coagul Fibrinolysis 27（7）：753-60, 2016_v1.0.pdf
9/2/2022 9:31 AM 957670 Ma AD et al.：Hematology Am Soc Hematol Educ Program ：432-437, 20_v1.0.pdf
9/2/2022 9:28 AM 621425 Maahs J et al.： J Blood Med 5： 153-156, 2014_v1.0.pdf
9/2/2022 9:42 AM 538545 Machado L. 2011 Emergency peripartum hysterectomy Incidence, ind_v1.0.pdf
9/2/2022 9:32 AM 135273 Mariani 2010_v1.0.pdf
9/2/2022 9:40 AM 128507 Mariani 2011_v1.0.pdf
9/2/2022 9:32 AM 846527 Mariani G et al.： Thromb Haemost 109(2)： 238-247, 2013_v1.0.pdf
9/2/2022 9:41 AM 4594086 Mavrides E, et al. 2016 Prevention and Management of Postpartum_v1.0.pdf
9/2/2022 9:43 AM 72690 Mehta 2004_v1.0.pdf
9/2/2022 9:42 AM 926627 Michelet D et al. 2015 Emergency hysterectomy for life-threateni_v1.0.pdf
9/2/2022 9:28 AM 498750 Monroe DM et al., Blood Coagul Fibrinolysis, 9(suppl 1)： S15-S20_v1.0.pdf
9/2/2022 9:31 AM 953313 Munn et al, 2016, J Haem Pract_v1.0.pdf
9/2/2022 9:32 AM 971088 Munn J Haem Pact_2016_v1.0.pdf
9/2/2022 9:41 AM 3616013 Muñoz M et al. 2019 Patient blood management in obstetrics preve_v1.0.pdf
9/2/2022 9:30 AM 512484 MX19NSVN0001- Ref 042_Watts_2005- use of rFVIIa for emergency fa_v1.0.pdf
9/2/2022 9:30 AM 735614 MX19NSVN0001- Ref 36a Rodriguez Merchan 2010 84-88 N7- Surgery i_v1.0.pdf
9/2/2022 9:40 AM 1407435 MX19NSVN00020- 13_Santagostino_2015_v1.0.pdf
9/2/2022 9:43 AM 1407435 MX19NSVN00021 Ref 13_Santagostino_2015_v1.0.pdf
9/2/2022 9:30 AM 1297323 MX19NSVN00021 Ref 25_Takedani_2014_v1.0.pdf
9/2/2022 9:32 AM 1019250 MX19NSVN00021 Ref 28_Salaj_2009_v1.0.pdf
9/2/2022 9:30 AM 18732 MX19NSVN00021 Ref 36_Laurian_2007_v1.0.pdf
9/2/2022 9:30 AM 789590 MX19NSVN00021 Ref 39_Banov_2014_v1.0.pdf
9/2/2022 9:30 AM 218822 MX19NSVN00021 Ref 41_Aouba_2010_v2.0.pdf
9/2/2022 9:30 AM 496668 MX19NSVN00021 Ref 46_Mehta_2004_v1.0.pdf
9/2/2022 9:28 AM 1054622 MX19NSVN00028- 25. Monroe 1997_v1.0.pdf
9/2/2022 9:28 AM 1329909 MX19NSVN00028- 6. Darby 2004_v1.0.pdf
9/2/2022 9:31 AM 1497859 MX20NSVN00008 17. Sumner Haemophilia 2007_v1.0.pdf
9/2/2022 9:39 AM 341806 Neufeld EJ et al. 2018 Haemophilia Recombinant activated factor_v2.0.pdf
9/2/2022 9:29 AM 1230656 Neufeld EJ et al.： Blood Rev 29（S1）：S34-S41, 2015_v1.0.pdf
9/2/2022 9:29 AM 769022 Neufeld, Pediatr Blood Cancer 2013; 60 1178-1183_v1.0.pdf
9/2/2022 9:31 AM 340626 Neufeld_et al, 2018, Haemophilia_v2.0.pdf
9/2/2022 9:39 AM 388395 Neufeld_Haemophilia_2018_v1.0.pdf
9/2/2022 9:28 AM 1159418 NHF - MASAC Guidelines, Dec 6, 2018_v1.0.pdf
9/2/2022 9:30 AM 1439894 NovoSeven® in the treatment of acqui·red hemophilia A results fr_v1.0.pdf
9/2/2022 9:28 AM 4583156 NovoSeven® Summary of Product Characteristics Nov 2020_v2.0.pdf
9/2/2022 9:31 AM 4328739 NovoSeven® Summary of Product Characteristics._v1.0.pdf
9/2/2022 9:32 AM 2725736 Nurden et al, 2012, Expert Rev Hematol_v1.0.pdf
9/2/2022 9:30 AM 154789 OBIZUR Summary of Product Characteristics November 2020_v3.0.pdf
9/2/2022 9:30 AM 394856 Odeyemi IA, Danø AM. Curr Med Res Opin 2009; 25(1) 239-250_v1.0.pdf
9/2/2022 9:31 AM 208559 Odeyemi IAO Odeyemi et al. Value Health. 2008;11(6)A633._v1.0.pdf
9/2/2022 9:29 AM 2086760 Odeyemi_2002_51-64_v1.0.pdf
9/2/2022 9:43 AM 208328 Odeyemi_2008_v1.0.pdf
9/2/2022 9:28 AM 421752 Oldenburg J et al. 2017 (HAVEN 1)_v1.0.pdf
9/2/2022 9:29 AM 1153026 Ozelo_2007_v1.0.pdf
9/2/2022 9:29 AM 1074282 Parameswaran R et al.Haemophilia 2005; 11 100-106_v1.0.pdf
9/2/2022 9:30 AM 404031 Pardos-Gea 2018_v1.0.pdf
9/2/2022 9:30 AM 172392 Polyanskaya T et al.： Haemophilia 18（6）： 997-1002, 2012_v1.0.pdf
9/2/2022 9:31 AM 578342 Poon MC et al, 2015 The international, prospective Glanzmann Thr_v1.0.pdf
9/2/2022 9:32 AM 552158 Poon MC, 2007, Vasc Health & Risk Man_v1.0.pdf
9/2/2022 9:40 AM 2650882 Poon, Haematologica. 2015;100(8)1038-44_v1.0.pdf
9/2/2022 9:29 AM 1142790 Pruthi et. al.Thrombosis and Haemostasis 2007; 98 726-732_v1.0.pdf
9/2/2022 9:29 AM 1080682 Putnam_2005_v1.0.pdf
9/2/2022 9:30 AM 147906 Rajic_2009_v2.0.pdf
9/2/2022 9:42 AM 1098773 Ramler P et al. 2017 Incidence, management and outcome ofwomen_v1.0.pdf
9/2/2022 9:40 AM 1243282 Ref 15 - Amano Haemophilia 2017_v1.0.pdf
9/2/2022 9:33 AM 1179318 Ref 18 - Borel-Derlon ACQUI 7 WFH 2016_v1.0.pdf
9/2/2022 9:30 AM 1373833 Ref 9 - Kruse-Jarres_et_al-2017-American_Journal_of_Hematology_v1.0.pdf
9/2/2022 9:40 AM 169224 Rodriguez-Merchan E et al 2004 Elective Orthopedic Surgery for H_v1.0.pdf
9/2/2022 9:30 AM 169860 Rodriguez-Merchan EC et al.： Semin Hematol 41（S1）：109-116, 2004_v1.0.pdf
9/2/2022 9:32 AM 1015389 Salaj et al, Haemophilia 2009; 15 752-59_v1.0.pdf
9/2/2022 9:29 AM 760066 Salaj et. al. Thrombosis Research 2012; 129 e233-37_v1.0.pdf
9/2/2022 9:32 AM 1014124 Salaj_2009_v1.0.pdf
9/2/2022 9:32 AM 207732 Santagostino E et al.： Blood Rev 29(S1)： S9-S18, 2015_v1.0.pdf
9/2/2022 9:29 AM 806449 Santagostino E et al.：Thromb Haemost 4(2)：367-371, 2006_v1.0.pdf
9/2/2022 9:29 AM 1959253 Shapiro AD et al.：Thromb Haemost 80（5）： 773-778, 1998_v1.0.pdf
9/2/2022 9:30 AM 615467 Shibeko 2014_v1.0.pdf
9/2/2022 9:42 AM 2234705 Sihler C et al. 2010 Complications of Massive Transfusion_v1.0.pdf
9/2/2022 9:43 AM 1545781 SmPC EN NovoSeven 2022-05_v2.0.pdf
9/2/2022 9:32 AM 1225045 Solh et al, 2015, Blood Med_v1.0.pdf
9/2/2022 9:40 AM 696882 Srivastava A et al, 2013, Haemphilia_v1.0.pdf
9/2/2022 9:33 AM 626487 Srivastava WFH_2012_Guidelines for the management of haemophilia_v1.0.pdf
9/2/2022 9:29 AM 1286475 Steen_2008_v1.0.pdf
9/2/2022 9:30 AM 2413613 Summary Basis for Regulatory Action - SevenFact 2019_v1.0.pdf
9/2/2022 9:40 AM 1613703 Sun et al 2019 British Journal of Haemotology_v1.0.pdf
9/2/2022 9:30 AM 58288 Takedani H et al.： Haemophilia 16（2）：290-295, 2010_v1.0.pdf
9/2/2022 9:40 AM 57737 Takedani_2010_v2.0.pdf
9/2/2022 9:42 AM 2101401 Taylor C et al. 2008 Immunological complications of blood transf_v1.0.pdf
9/2/2022 9:32 AM 132032 The incidence of factor VIII and factor IX inhibitors in the hem_v1.0.pdf
9/2/2022 9:28 AM 90038 The need for speed in the management of haemophilia patients wit_v1.0.pdf
9/2/2022 9:42 AM 979083 Thurn L et al. 2018 Postpartum blood transfusion and hemorrhage_v1.0.pdf
9/2/2022 9:31 AM 1033830 Tiede A et al 2015 The use of recombinant activated factor VII i_v1.0.pdf
9/2/2022 9:31 AM 1996041 Tiede A et al.：Ann Hematol 97（10）：1889-1901, 2018_v1.0.pdf
9/2/2022 9:33 AM 1209892 Tiede A et al.：Semin Thromb Hemost 40：803-811, 2014_v1.0.pdf
9/2/2022 9:39 AM 1026927 Tiede, A. et al 2015 Management of acquired haemophilia_v2.0.pdf
9/2/2022 9:40 AM 107553 Valentino LA et al 2011 Surgical Experience with rFVIIa (NovoSev_v1.0.pdf
9/2/2022 9:30 AM 105971 Valentino LA et al.： Haemophilia 17（4）： 579-589, 2011_v1.0.pdf
9/2/2022 9:31 AM 721014 Vintimilla M et al.：Arthritis Care Res 62（7）：1047-50, 2010_v1.0.pdf
9/2/2022 9:40 AM 703602 Wallach JB 2007 Interpretation of diagnostic tests_v1.0.pdf
9/2/2022 9:31 AM 705699 Wallach JB. Interpretation of Diagnostic Tests. 8th ed. Philadel_v1.0.pdf
9/2/2022 9:30 AM 1458378 Wang 2017_v1.0.pdf
9/2/2022 9:32 AM 1275285 Weeterings, 2008, Blood_v1.0.pdf
9/2/2022 9:28 AM 10065753 World Federation of Hemophilia (WFH) Guidelines Guidelines for t_v1.0.pdf
9/2/2022 9:43 AM 696682 World Hemophilia Federation (WFH) Guidelines Guidelines for the_v1.0.pdf
9/2/2022 9:29 AM 911701 Young et al, Haemophilia 2008; Slide 08, 09 & 10 ref 1 287-294_v1.0.pdf
9/2/2022 9:32 AM 1235619 Young G et al.： Haemophilia 14(2)： 287-294, 2008_v1.0.pdf
9/2/2022 9:42 AM 772291 Zhang Y et al. 2017 Emergency obstetric hysterectomy for_life-th_v1.0.pdf